BIO-WindhoverMar. 16, 2008-Mar. 18, 2008
New York, NY
Preserving Value: To License or Not to LicenseBen Bonifant, Vice President and head of the Business Development Practice, will participate in the opening keynote panel discussion titled "Preserving Value: To License or Not to License." Other panelists include Pfizer, Atlas Venture, Alnylam Pharmaceuticals, and Deerfield Partners.
Preserving Value: To License or Not to License
With M&A increasingly popular among Big Pharma and the overwhelmingly preferred exit for VCs, whether or not to license a key product (and how much of the key product’s rights to license) has become one of the most important strategic challenges for biotechs and their investors. Forgo a significant licensing opportunity -- and forgo the most important source of non-dilutive financing. License out the project -- and potentially destroy the value for a deep-pocketed acquirer. This panel of venture and cross-over investors and biotech companies who have made very different choices about licensing strategies will discuss how they have grappled with the myriad problems embedded in the licensing decision.